Regulus Therapeutics
RGLS
#7427
Rank
A$0.79 B
Marketcap
A$11.45
Share price
0.00%
Change (1 day)
398.42%
Change (1 year)

Earnings for Regulus Therapeutics (RGLS)

Earnings in 2025 (TTM): -A$72.73 Million

According to Regulus Therapeutics's latest financial reports the company's current earnings are N/A. In 2024 the company made an earning of -A$64.82 Million a decrease over its 2023 earnings that were of -A$41.3 Million. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Regulus Therapeutics from 2012 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) -A$72.73 Million12.2%
2024 -A$64.82 Million56.97%
2023 -A$41.3 Million6.51%
2022 -A$38.77 Million2.53%
2021 -A$37.81 Million93.59%
2020 -A$19.54 Million-15.41%
2019 -A$23.09 Million-64.46%
2018 -A$64.96 Million-33.26%
2017 -A$97.34 Million-13.98%
2016 -A$0.12 Billion44.77%
2015 -A$78.17 Million-1.63%
2014 -A$79.47 Million203.6%
2013 -A$26.18 Million8.65%
2012 -A$24.09 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Sanofi
SNY
A$10.74 B-16,247.25%๐Ÿ‡ซ๐Ÿ‡ท France
Biogen
BIIB
A$2.27 B-3,521.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
A$13.46 B-20,334.46%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
A$20.57 B-31,017.79%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
A$14.04 B-21,208.18%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sangamo Therapeutics
SGMO
-A$0.16 Billion 132.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
-A$0.17 Billion 148.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
A$1.22 B-1,933.62%๐Ÿ‡บ๐Ÿ‡ธ USA